Compare SE & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SE | REGN |
|---|---|---|
| Founded | 2009 | 1988 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.8B | 79.4B |
| IPO Year | 2017 | 1995 |
| Metric | SE | REGN |
|---|---|---|
| Price | $92.35 | $759.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 23 |
| Target Price | $179.54 | ★ $815.04 |
| AVG Volume (30 Days) | ★ 6.9M | 638.2K |
| Earning Date | 01-01-0001 | 04-16-2026 |
| Dividend Yield | N/A | ★ 0.49% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | N/A | ★ 41.48 |
| Revenue | N/A | ★ $5,872,227,000.00 |
| Revenue This Year | $25.20 | $11.69 |
| Revenue Next Year | $17.80 | $10.12 |
| P/E Ratio | $49.15 | ★ $18.41 |
| Revenue Growth | N/A | ★ 20.82 |
| 52 Week Low | $77.05 | $476.49 |
| 52 Week High | $199.30 | $821.11 |
| Indicator | SE | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 34.73 | 45.70 |
| Support Level | N/A | $740.39 |
| Resistance Level | $161.37 | $786.67 |
| Average True Range (ATR) | 4.96 | 21.54 |
| MACD | -1.41 | -2.98 |
| Stochastic Oscillator | 37.87 | 18.91 |
Sea started as a gaming business, Garena, but in 2015 expanded into e-commerce. Sea operates Southeast Asia's largest e-commerce company, Shopee, in terms of gross merchandise value. Shopee is a hybrid C2C and B2C marketplace platform operating in Indonesia, Taiwan, Vietnam, Thailand, Malaysia, the Philippines, and Brazil. For Garena, Free Fire is the key revenue generating game. Sea's third business, SeaMoney, provides lending, payment, digital banking, and insurance services.As of March 31, 2025, Forrest Xiaodong Li, the founder, chairman and CEO, owned 59.1% of voting power. Tencent owned 18.5% of issued shares with no voting power.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).